Sodium cromoglicate veterinary-grade API is a crystalline powder supplied for conversion into sterile ophthalmic solutions, injectable solutions, oral tablets, capsules, powders, granules, and medicated premixes. The substance is the disodium salt of 5,5′-[(2-hydroxy-1,3-propanediyl)bis(oxy)]bis[4-oxo-4H-1-benzopyran-2-carboxylic acid], CAS 15826-37-6, molecular weight 512.33 g/mol. The solid is white to off-white and hygroscopic, and its high aqueous solubility permits single-phase ophthalmic solutions while also creating formulation constraints in oral solid dosage forms because rapid dissolution can alter local fluid properties in the gastric environment and affect disintegration profiling. Pharmacopoeial release specifications typically include assay on the dried basis within 98.0%–102.0%, loss on drying at 105 °C of not more than 10.0%, pH of a 1% aqueous solution between 6.0 and 7.5, and related substances by liquid chromatography. The API is offered in three controlled grades: non-micronised powder, micronised powder, and sterile micronised grade for aseptic formulation. Veterinary suitability is established through the declared manufacturing process, residual solvent profile, elemental impurity data generated under USP <232>/<233> or Ph. Eur. 2.4.35, and supply-chain documentation confirming the absence of substances prohibited in food-producing species under EU Regulation 2019/6 and 21 CFR 530.

Mechanistically the API is not an antihistamine. It inhibits antigen-induced degranulation of mast cells by stabilising the mast cell membrane. This distinction has direct formulation consequences: sodium cromoglicate must be present in the target tissue compartment before mast cell activation. The molecule’s high water solubility and low octanol-water partitioning direct it toward aqueous tear film retention or gastrointestinal mucosal contact rather than transcellular absorption. Published pharmacokinetic data for oral bioavailability in dogs and horses show low systemic exposure; this is an expected property arising from the ionised carboxylate groups at physiological pH. Oral dosage forms are therefore frequently designed for local gastrointestinal mast cell stabilisation, while ophthalmic solutions are formulated with viscosity-modifying polymers to extend precorneal residence time. The absence of primary amine functionality differentiates sodium cromoglicate from amine-containing antihistamines and reduces the potential for Maillard-type browning reactions with reducing-sugar tablet excipients.

Why Does pH Control Become Critical When Formulating Sodium Cromoglicate Solutions?

The two carboxylate residues in the cromoglicate anion are ionisable; the pharmacopoeial pH window of 6.0–7.5 for a 1% solution is therefore not arbitrary. At acidic pH, the free acid form can precipitate as a poorly soluble solid, producing loss of optical clarity in ophthalmic solutions and increased particulate counts. At alkaline pH, the chromone ring system becomes more susceptible to hydrolytic degradation, and the rate constant for benzopyran ring opening rises with hydroxide ion concentration. Buffered ophthalmic vehicles are maintained near physiological pH, typically 6.8–7.4, with phosphate or citrate buffer systems selected to avoid buffer-capacity interactions with tear fluid. For injectable solutions, finished pH must also be compatible with venous tolerability; pH adjustment with dilute hydrochloric acid or sodium hydroxide is performed before final dilution. Sterile filtration through 0.22 µm polyvinylidene fluoride or polyethersulfone membranes is the standard route for ophthalmic and parenteral products. Terminal steam sterilisation at 121 °C for 15 minutes should be used only when supported by forced degradation data specific to the formulation because the ester-like ether linkages in the molecule are potentially hydrolysable at elevated temperature.

Particle-size control becomes route-specific. For clear ophthalmic solutions, the API is dissolved and filtered, so bulk particle size is subordinate to dissolution time and solution filterability. For oral powders and granulated premixes, particle-size distribution directly controls mix homogeneity and segregation. Non-micronised API with a laser diffraction D90 in the 100–150 µm range may be acceptable for direct inclusion in premix blends that are subsequently diluted with lactose or dextrose carriers; micronised API with D90 ≤10 µm may be specified for ocular suspension or inhalation-type applications, although published data for this specific veterinary configuration is limited. Laser diffraction measurement is performed under ISO 13320:2020, and analytical sieving may be performed under Ph. Eur. 2.9.38 or USP <786>. Bulk density and tapped density should be specified using Ph. Eur. 2.9.34 because flowability in capsule filling and tablet die fill depends on both particle shape and residual moisture. The same API lot can be released for multiple routes only when the Certificate of Analysis includes route-appropriate tests for particle size, endotoxin, and residual solvents.

When Wet Granulation Is Selected for Sodium Cromoglicate Tablet Blends

Wet granulation is feasible but must be controlled. Sodium cromoglicate is hygroscopic, and local overwetting in a high-shear granulator can produce tacky agglomerates and a bimodal granule size distribution. Granulation endpoint is monitored by impeller power consumption or near-infrared moisture rather than fixed granulation time. Drying in a fluidised bed dryer to residual moisture below 3.0% w/w is typical before lubrication. Magnesium stearate should be kept at or below 1.0% w/w because higher concentrations can form a hydrophobic film on the water-soluble API and delay disintegration. Disintegration is measured by Ph. Eur. 2.9.1 or USP <701>; immediate-release veterinary tablets are commonly specified to disintegrate within 15 minutes in water at 37 °C, but the approved target is product-specific.

During formulation development, a saturated solubility screen in water at 25 °C and 37 °C is used to define sink conditions for dissolution testing. For immediate-release tablets and capsules, dissolution media of 900 mL water or 0.1 M hydrochloric acid are selected according to product-specific monographs; the high aqueous solubility often produces rapid release, so a discriminating dissolution method may require lower agitation or a pH-shift design. BCS-based biowaivers are not automatically accepted for veterinary products, and dissolution specifications should be linked to in vivo relevance where possible. For ophthalmic solutions, dissolution testing is less critical than tonicity and clarity; osmolality is typically adjusted to 280–320 mOsm/kg with sodium chloride or mannitol, and viscosity may be raised with hypromellose or polyvinyl alcohol to prolong ocular residence time.

Compliance Boundaries for Sterile Ophthalmic and Injectable Dosage Forms

Injectable sodium cromoglicate solutions require more stringent API release controls than oral powders. Bacterial endotoxins in the API should be controlled by Ph. Eur. 2.6.14 or USP <85>, with the acceptance limit derived from the maximum endotoxin dose per kg. A typical injectable solution at 20 mg/mL may require an API endotoxin limit of ≤0.5 EU/mg if the product-specific calculation permits, but this is not a universal value. Particulate matter in the finished injectable is controlled under USP <788> or Ph. Eur. 2.9.19; ophthalmic products are controlled under USP <789> or Ph. Eur. 2.9.20. Sterility assurance relies on membrane filtration and aseptic fill, with media fill validation conducted to demonstrate a failure rate below 0.1% confidence limits. The API itself is not assumed sterile unless a sterile-grade contract is in place; therefore microbial enumeration and specified-organism tests under Ph. Eur. 2.6.12/2.6.13 or USP <61>/<62> are used for non-sterile material.

Compared with ketotifen fumarate, sodium cromoglicate has a narrower pharmacodynamic profile: it is primarily a mast cell stabiliser, whereas ketotifen also blocks H1 receptors. Compared with nedocromil sodium, sodium cromoglicate has a longer history of veterinary use but a lower potency on a milligram basis in some in vitro assays; direct substitution in a formulation is therefore not automatically valid. Compared with corticosteroid ophthalmic APIs such as prednisolone acetate, sodium cromoglicate does not share corticosteroid-associated mechanisms and is not intended for acute suppression of corneal inflammation. In solid dosage forms, the absence of a primary amine and the high water solubility of sodium cromoglicate distinguish it from amine-bearing antihistamines and from poorly soluble corticosteroids, respectively. These differences influence excipient selection: reducing sugars are less problematic than with primary amine APIs, but wet granulation must still manage hygroscopicity. Where historical veterinary formulations have used sodium cromoglicate as a local mast-cell stabiliser, switching to a different mast cell stabiliser requires revalidation of dissolution, homogeneity, and eye-drop osmolality because the dose-response and physicochemical profiles are not interchangeable.

The API is quantified by reversed-phase HPLC with ultraviolet detection at approximately 254 nm or by non-aqueous titration. The chromone chromophore provides a strong UV response, permitting related substance separation on a C18 column with a phosphate buffer-acetonitrile mobile phase. System suitability criteria include resolution between cromoglicic acid and adjacent impurity peaks not less than 2.0, tailing factor not more than 2.0, and relative standard deviation of replicate injections not more than 1.0%. Analytical methods for trace-level impurities should be validated according to ICH Q2(R2). For food-producing animals, withdrawal periods are not defined by the API alone but by the authorised veterinary medicinal product; therefore the API documentation should state that the material is intended for veterinary pharmaceutical manufacture and not for direct administration. The API is supplied as a single chemical entity; no preservative is included unless specified in a custom technical grade, because benzalkonium chloride or chlorobutanol are added only in finished ophthalmic solutions.

For medicated premixes intended for feed incorporation, the primary technical risk is segregation of the API during storage and transport. Sodium cromoglicate has a higher particle density and different shape from typical feed carriers, so a stepwise mixing sequence is required. A conservative procedure is to prepare a 1:10 preblend with lactose monohydrate or dextrose, mix for 10 minutes in a V-blender, and then dilute to the final concentration. Finished premix homogeneity should be verified by assay of 10 sampling points with an acceptance value for content uniformity based on Ph. Eur. 2.9.40 or USP <905> for pharmaceutical dosage forms, unless feed-medicament criteria apply. For oral granules dispersed in feed or water, the API’s high water solubility can be exploited to prepare aqueous stock solutions, but solution stability after reconstitution must be confirmed because microbial growth in non-preserved water can occur within 24 hours at room temperature. If in-feed stability is required, the API should be protected from moisture and direct sunlight; humidity above 60% can cause caking and loss of homogeneity in uncoated granules. The API is normally packed in double polyethylene bags inside a fibre drum or triple-laminated aluminium pouch, with a desiccant sachet for hygroscopic grades. Transport should be maintained at 15–25 °C and RH ≤40% for long-term storage, and re-sealed containers should not be exposed to repeated humidity cycles because hydration can alter the powder’s mechanical properties and subsequent granulation behaviour.